OliX Pharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor (US 10,301,628) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Jan 23, 2027The maintenance fee for Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1 (US 10,358,648) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
- 2 fees due Jun 24 to 30, 2027 · next Jun 24
- 1 fee due Sep 17, 2027The maintenance fee for Treatment of Age-Related Macular Degeneration Using RNA Complexes That Target MYD88 or TLR3 (US 10,590,423) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,214,744 | Nucleic acid molecules inducing RNA interference, and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,829,760 | Nucleic acid molecules inducing RNA interference, and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,637,742 | Nucleic acid molecules inducing RNA interference, and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,125,362 | RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 10,883,105 | RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 10,064,801 | RNA complexes that inhibit melanin production In force · From the USPTO record | In force | From the USPTO record | |
| US 10,512,600 | RNA complexes that inhibit melanin production In force · From the USPTO record | In force | From the USPTO record | |
| US 10,059,949 | Treatment of Age-Related Macular Degeneration Using RNA Complexes That Target MYD88 or TLR3 In force · High confidence | In force | High confidence | |
| US 10,590,423 | Treatment of Age-Related Macular Degeneration Using RNA Complexes That Target MYD88 or TLR3 In force · Low confidence | In force | Low confidence | |
| US 10,358,648 | Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1 In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 3 no status recorded